Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is well-positioned in the peripheral nerve repair market with its innovative products and strong clinical data supporting their efficacy. With the recent FDA approval of their Avance Nerve Graft, Axogen is now able to target even more patients in need of peripheral nerve repair. The company's strong financial performance, with a 27% year-over-year revenue growth in the first quarter of 2026, and a positive outlook for future revenue growth, make it an attractive investment opportunity.

Bears say

Axogen is showing promising signs of increased revenue growth, with a projected 20% year-over-year increase in FY26 and continued growth potential through 2028. However, recent product cost pressure and the uncertainty of potential payer coverage rulings may hinder profitability in the near future. Despite management's commitment to positive free cash flow for the year, the company's financials may need to be closely monitored as these factors could impact their long-term growth strategy.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.